Cognizant is harnessing the power of generative AI (gen AI) technology in collaboration with the NVIDIA BioNeMo platform to tackle the intricate challenges of drug discovery within the life sciences industry. 

The aim is to enhance productivity in the development process and accelerate the pace at which life-saving treatments can reach the market. Traditional methodologies for drug discovery are infamous for being laborious, involving extensive analysis of scientific literature and clinical data to uncover crucial insights. Additionally, these conventional approaches are plagued by exorbitant costs and protracted development lifecycles, often resulting in a high failure rate. 

By leveraging gen AI technologies, clinical researchers can efficiently navigate through vast datasets, accurately predict interactions between drug compounds, and forge new, viable pathways for drug development.

Anna Elango, EVP of Cognizant's Core Technologies and Insights, emphasized the transformative potential of generative AI, stating, "More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all."

Through a strategic partnership with NVIDIA, Cognizant aims to pave the way for this vision to become a reality for its life sciences clients. By combining Cognizant's deep domain expertise in life sciences and AI with NVIDIA's pre-trained, industry-specific generative AI models offered through BioNeMo, clients gain access to a comprehensive suite of model-making services. These services include pre-trained models, cutting-edge frameworks, and APIs, enabling clients to swiftly train and customize enterprise models using their proprietary data, with minimal manual intervention and without the need for extensive coding or infrastructure maintenance.

Alvin DaCosta, VP of Global Consulting Partner Organization at NVIDIA, highlighted the potential impact of generative AI on enterprise productivity, stating, "Generative AI will drive the next wave of enterprise productivity gains across industries, enabled by the NVIDIA AI Enterprise software platform."

Cognizant's collaboration extends across leading global firms in pharmaceuticals, biotech, and medical devices, covering the entire life sciences value chain from research and development to digital health. This collaborative effort aims to enhance scientific advancements, improve patient outcomes, and increase business value by fostering a patient-centric approach and enhancing interactions with healthcare professionals.

Looking ahead, Cognizant plans to explore additional applications in collaboration with NVIDIA, particularly in sectors such as manufacturing and automotive engineering, where gen AI holds the potential to boost productivity, streamline costs, and accelerate innovation. 

The company is poised to establish an NVIDIA AI Center of Excellence this year to further innovate with NVIDIA technologies, including the NVIDIA Metropolis, NVIDIA Omniverse, and NVIDIA AI Enterprise platforms, for the benefit of clients across industries globally.